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1. Introduction  
Alpha-1 antitrypsin (AAT) deficiency is a hereditary disorder associated with mutations in 
the SERPINA1 gene (Kelly et al., 2008; Greene et al., 2008). Over 100 different alleles have 
been identified however the most common disease-causing mutation, termed Z, encodes a 
glutamic acid to lysine substitution at position 342 of the mature AAT protein. As a member 
of the serine proteinase inhibitor family, the role of AAT is to inhibit serine proteases 
throughout the body but principally in the lung. The ZAAT protein fails to adopt the correct 
protein conformation and polymerises and accumulates intracellularly in AAT-producing 
cells. The liver is the major source of the body’s pool of AAT. The major consequences of 
ZAAT accumulation in hepatocytes are toxic gain of function events leading to endoplasmic 
reticulum (ER) expansion and dilation and activation of multiple ER stress signalling 
pathways (Lomas et al., 1992; Teckman & Perlmutter, 2000; Lawless et al., 2004; Hidvegi et 
al., 2005; Hidvegi et al., 2007; Miller et al., 2007). These predispose to liver failure. The 
second major clinical consequence of ZAAT deficiency is a lower than normal antiprotease 
protective screen throughout the body, but most importantly in the lung (Lomas et al., 
1993). ZAAT deficient individuals can develop emphysematous lung disease as early as in 
their 4th decade.   
Gene therapies to treat both aspects of the disease are currently at various stages of 
development. For the liver disease approaches that can be considered include ribozymes, 
antisense, peptide nucleic acids and small-interfering RNAs; all designed to inhibit 
expression of the mutant gene (recently reviewed in McLean et al., 2009). For the lung 
disease gene therapies using non-viral, lentiviral and adeno-associated viral approaches to 
express the normal gene either locally or intramuscularly have been reported (Chulay et al., 
2011; Brantly et al., 2006; Flotte et al., 2007; Argyros et al., 2008; Brantly et al., 2009; Liqun 
Wang et al., 2009); all aim to increase AAT levels in the circulation above the deficiency 
threshold of 11 µM. New approaches are focused on coupling haematopoietic stem cell 
therapy with AAT-lentiviral gene therapy (Ghaedi et al., 2010; Argyros et al., 2008).  This 
chapter will review the history and current state-of-the-art in these areas. 
2. Gene therapies targeting ZAAT-related liver disease  
There are currently no available treatments for AAT deficiency-related liver disease other 
than transplantation. The 5-year survival is 83% for adults and 90% for children post 
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transplant (Kemmer et al., 2008). As an alternative to transplantation gene therapy 
approaches aimed at inhibiting ZAAT expression in the liver can potentially be used to stop 
the production of the mutant Z protein, hence prohibiting the accumulation of the protein in 
the liver and providing protection against liver disease. Such approaches include the use of 
ribozymes, small interfering RNA (siRNA) and small DNA fragments (SDF), and a number 
of these genetic approaches designed to downregulate ZAAT expression have been tested in 
animals as therapies for liver disease in AAT deficiency. To date there have been no reports 
on the use of zinc-finger nucleases (ZFN) or peptide nucleic acids (PNA) to treat ZAAT-
related liver disease (Figure 1). ZFNs are artificial restriction enzymes that can be 
engineered to target specific DNA sequences and exploit a cell’s DNA repair machinery to 
precisely alter the genome; PNAs are synthetic DNA analogues that hybridize to 
complementary DNA or RNA to facilitate anti-gene or antisense inhibition, respectively 
(Jensen et al., 1997; Pellestor & Paulasova, 2004).  It has been suggested that if ZAAT levels 
can be decreased to those similar or lower than MZ AAT heterozygotes there may be clinical 
benefit (Cruz et al., 2007) as heterozygous individuals rarely develop severe liver disease, 
particularly in childhood. 
2.1 Ribozymes  
Ribozymes are catalytic RNA molecules capable of cleaving RNA with high specificity.  
Their catalytic properties were discovered almost 30 years ago (Kruger et al., 1982) and they 
are now known to contain both a catalytic RNA domain that cleaves a target mRNA and a 
substrate-binding domain that contains an antisense sequence to the target mRNA sequence 
that enables them to bind to their target mRNA sequence through Watson–Crick base 
pairing (Trang et al., 2004). The best characterised ribozymes have hammerhead or hairpin 
shaped active centres; both are promising gene-targeting reagents.   
Hammerhead ribozymes capable of cleaving AAT mRNA have been constructed and were 
shown to be effective at inhibiting ZAAT expression in a human hepatoma cell line (Zern et 
al., 1999). In this study the hepatoma cells were also stably transduced with a modified AAT 
cDNA capable of producing wildtype AAT protein, but resistant to cleavage by the ZAAT-
targetted ribozyme. Later a bi-functional vector was constructed, which contained both the 
ribozyme and the ribozyme-resistant AAT gene. Once transduced into hepatoma cells, the 
cells showed effective expression of the transduced AAT under conditions where the 
endogenous AAT gene was inhibited (Ozaki et al., 1999). Effective gene therapy for ZAAT 
deficiency requires stable transduction of resting hepatocytes, ideally to deliver both wild-
type AAT and to inhibit production of ZAAT. Duan et al. treated transgenic mice expressing 
the human ZAAT allele with a simian virus 40 (SV40)-derived vector carrying a ribozyme 
designed to target the human transcript. The mice showed a marked decrease of human 
AAT mRNA and protein in the liver, and serum levels of human AAT were decreased by up 
to 50% 3-16 weeks after transduction (Duan et al., 2004).  
Together these data show promise for the use of ribozymes for ZAAT-related liver disease. 
Importantly ribozymes bind to their targets with high specificity however there can be 
problems with their use to knockdown gene expression in vivo as their activity in vivo is not 
usually sufficient to achieve the desired effects. 
2.2 Small interfering RNA  
RNA interference (RNAi) is the process of sequence-specific, post-transcriptional gene 
silencing. It is initiated by short double-stranded RNA (dsRNA) sequences called small 
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Fig. 1. Gene therapies for ZAAT-related liver disease. The Z mutation (shown by the red 
star) can be repaired using small DNA fragments (SDF) or zinc finger nucleases. Peptide 
nucleic acids (PNA) can inhibit the processes of transcription or translation whilst 
ribozymes (Rz) and siRNA target the mRNA and inhibit translation. 
interfering RNA (siRNA) that are generated from longer transcripts by the enzyme Dicer.  
Each siRNA has specificity for a target RNA via its homology to sequences within the target 
gene (Elbashir et al., 2001). siRNAs form part of the RNA-induced silencing complex (RISC), 
a multi-component nuclease containing RNAse III, that enables the destruction of target 
mRNAs (Hammond et al., 2000). The argonaute protein within RISC incorporates one strand 
of an siRNA, known as the guide strand, and uses this as a template for recognizing 
complementary mRNA. Once found the target mRNA is cleaved by activation of the RNAse 
activity within RISC. 
The delivery in vivo of siRNAs by liposomes or cationic lipids has been described.  Other 
strategies for local or systemic administration of siRNA include electropulsation, delivery by 
viral vector, chemical modifications of siRNA molecules or polyamine or other 
encapsulation technologies. Targetting siRNAs directly to the liver can be achieved by local 
administration via injection through the hepatic portal vein and can prevent unwanted 
effects on normal host tissues. In 2007 studies describing the use of siRNAs designed to 
downregulate endogenous AAT within hepatocytes were reported. Using an adeno-
associated virus (AAV) backbone three separate siRNA sequences were transduced singly 
or as a trifunctional construct into cell culture models. Whilst each siRNA had activity 
independently, the levels of AAT expression showed the greatest decrease, up to five-fold 
lower than controls, with the trifunctional construct. Following packaging of this construct 
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into an AAV serotype 8 capsid, and transduction into the livers of transgenic mice 
overexpressing human ZAAT, a decrease in total and monomer ZAAT levels coupled with 
reversal of ZAAT accumulation was evident within the liver up to 3 weeks after vector 
injection (Cruz et al., 2007).  
2.3 Small DNA fragments  
The use of small DNA fragments (SDF) for homologous replacement of mutant genes allows 
targets to be directly altered by insertion, deletion or replacement.  Theoretically direct 
conversion of the mutant sequence to a wild-type genotype ensues, thereby restoring the 
normal phenotype.  The basis of this technology involves the introduction of small DNA 
fragments into cells that recombine with the genomic DNA at a targeted site, thereby 
producing a specific change in the sequence. The feasibility of using SDF targeting the AAT 
gene has been reported.  SDFs encoding the normal AAT sequence were generated and 
transfected ex vivo into peripheral blood monocytes from control and ZAAT deficient 
individuals.  The SDFs corrected the defective gene in ZAAT monocytes and treatment was 
associated with an increase in AAT secretion.  A similar methodology to repair the ZAAT gene 
defect in hepatocytes should have beneficial effects on secretion, and could ultimately lead to 
protection of both the lung and liver in ZAAT deficient individuals (McNab et al., 2007).  
3. Gene therapies to target ZAAT-related lung disease  
There have been a number of gene therapy trials for the treatment of AAT deficiency-related 
lung disease. The first used cationic liposomes encapsulating a plasmid carrying the human 
AAT cDNA (Brigham et al., 2000). In this open-label study the liposomes were administered 
intranasally to 5 ZAAT deficient individuals. The results showed that AAT levels were 
increased at day 5 following administration and returned to baseline by day 14. Subsequent 
studies have improved on this by using non-pathogenic human parvovirus recombinant 
AAV vectors that are more efficient at transgene delivery and are more capable of extended 
transgene expression.  
3.1 Intramuscular adeno-associated viral gene delivery  
In 2006 Brantly et al. reported their results from a phase I trial of intramuscular injection of a 
recombinant adeno-associated virus serotype 2 vector (rAAV2) carrying the human AAT 
gene into 12 AAT deficient adults (Brantly et al., 2006). Subjects were divided into groups of 
three and allocated to one of four dose cohorts ranging from 2.1 x 1012 to 6.9 x 1013 vector 
genomes. Each was injected into the deltoid muscle of their non-dominant arm sequentially 
in a dose-escalating fashion. No vector-related adverse events occurred in any of the 
participants although anti-rAAV2 capsid antibodies were present and rose after vector 
injection. In this study just one subject exhibited low-level expression of wild-type AAT in 
their serum (82 nM) up to 30 days after receiving an injection of 2.1 x 1013 vector genomes. 
Residual AAT levels from previous AAT protein replacement therapy was blamed for 
interfering with the detection of any possible vector expression in most of the other 
individuals. 
Later in another phase 1, open-label, dose-escalation clinical trial sustained AAT expression 
was achieved using a rAAV serotype 1 vector (Brantly et al., 2009). rAAV1 is substantially 
more efficient than rAAV2 in transducing skeletal muscle (Cruz et al., 2007). Once again 
subjects were dosed via intramuscular (i.m.) injection and those subjects who had been 
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receiving protein therapy discontinued its use for 28 or 56 days prior to vector 
administration. In those who received 2.2 x 1013 and 6.0 x 1013 vector genome particles 
normal AAT was expressed above background in all subjects. AAT expression was 
sustained at levels 0.1% of normal for at least 1 year in the highest dosage level cohort. 
Vector administration was well tolerated and there were no changes in hematology or 
clinical chemistry parameters however neutralizing antibody and IFN-gamma enzyme-
linked immunospot responses to rAAV1 capsid were evident in all subjects at day 14.  
The most recent report on this gene therapy approach describes the results of a preclinical 
evaluation of a rAAV1 vector expressing human AAT made using a recombinant herpes 
simplex virus production method that can achieve much higher yields enabling a substantial 
increase in dosage in clinical studies (Chulay et al., 2011). The toxicology study in mice 
treated i.m. with this vector showed that the HSV-produced vector had favorable 
characteristics in terms of purity, efficiency of transduction, and human AAT expression.  
 
 
Fig. 2. Gene therapy strategies for ZAAT-related lung disease. The normal AAT gene can be 
introduced via intramuscular injection of an AAT-expressing adeno-associated virus (AAV) 
leading to production of normal AAT protein. Alternatively a patient’s own cells can be 
harvested, induced to pluripotency (iPSCs) and the defect corrected ex vivo prior to 
autologous cell therapy. 
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Administration with this vector led to no significant differences in clinical findings or 
hematology and no gross changes in pathology although there were mild changes in skeletal 
muscle at the injection site. These consisted of focal chronic interstitial inflammation and 
muscle degeneration, regeneration and vacuolization in vector-injected animals. Vectors 
were detectable in blood 24 hours after dosing and declined thereafter, with no copies 
detectable 90 days after dosing. Antibodies to human AAT were detected in almost all 
treated animals, with antibodies to HSV detectable in most animals that received the highest 
vector dose. With higher doses of HSV-produced vector, the increase in serum human AAT 
levels was dose-dependent in females and, interestingly, greater than dose-proportional in 
males. Together all of these studies support continued development of rAAV1-AAT vectors 
for i.m. gene delivery for the treatment of AAT deficiency (Figure 2). 
3.2 Viral gene delivery to the lung  
Transduction of cells within the lung is an attractive approach for AAT gene therapy. Since 
somatic tissues are comprised of heterogeneous, differentiated cell lineages that can be 
difficult to specifically transfect (although this may have been largely overcome by the work 
of Flotte using i.m. injection (section 3.1)), methods have been tested to deliver gene 
therapies directly to cells within the lung. These include AAV and other viral methods to 
deliver the AAT gene directly to cells within the lung for local expression of AAT at the site 
where it is most needed to provide an antiprotease protective screen. Both integrating 
lentiviral systems and non-integrating AAV vectors are capable of gene transfer and 
expression in vivo in non-dividing cells and approaches using both viruses have been 
undertaken. Using recombinant AAV vectors Liqun Wang et al. evaluated the transduction 
and expression efficiencies of several rAAV serotypes and rAAV2 capsid mutants with 
specific pulmonary targeting ligands (Liqun Wang et al., 2009). Noninvasive intranasal 
delivery was compared with intratracheal lung delivery into the mouse lung. Of all the 
vectors tested they found that recombinant rAAV8 was the most efficient serotype at 
expressing AAT in the lung. Intratracheal administration was superior to intranasal delivery 
for most vectors. Limberis et al. also characterized a wide range of vectors and nine different 
serotypes of rAAV for their ability to transduce mouse and human ciliated airway 
epithelium (Limberis et al., 2009).  In their studies rAAV5 and rAAV6 were found to be the 
most efficient at transducing mouse epithelium whilst only rAAV6 was as effective in 
human cells. Variants of AAV6 with targeted mutations were also tested. One of these, 
rAAV6.2, was more efficient than all the other rAAV vectors tested and shows promise for 
development and preclinical testing. In a separate AAT-rAAV6 study involving delivery to 
the lungs of mice and dogs, administrations led to increased and extended intrapulmonary 
AAT levels, however the animals developed immune responses including a 
lymphoproliferative response to the AAV capsid (Halbert et al., 2010). Another approach 
using intratracheal instillation of an AAT lentiviral system led to successful selective 
delivery of the AAT transgene to alveolar macrophages in the mouse lung (Wilson et al., 
2010). These cells persisted in the alveoli and expressed AAT for the lifetime of the adult 
mouse and achieved localized secretion of therapeutic levels of AAT protein into the airway 
epithelial lining fluid.  Using a mouse model of emphysema this approach ameliorated the 
progression of emphysema without inducing humoral or cellular immune responses.  
3.3 Stem cell therapy and other approaches to gene delivery  
An ideal gene therapy approach should enable persistent transgene expression without 
limitations of safety and reproducibility. Using an individual’s own cells, cultured in vitro as 
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the delivery platform for gene therapy is a new approach that can potentially circumvent 
these problems. The use of stem cells, either the induced pluripotent form or 
hematopoietic/mesencymal derived, has been considered for AAT gene therapy. For 
example, lentivirally transduced murine hematopoietic stem cells (HSCs) expressing a 
human AAT transgene have been developed (Wilson et al., 2008). Once transplanted into 
irradiated mouse recipients these HSCs maintained their multipotency, self-renewal 
potential, and could reconstitute the hematopoietic systems of both primary and secondary 
recipients. Furthermore these lentivirally-modified cells generated sustained and systemic 
expression of AAT in vivo for over 30 weeks. Other genetically modified mesenchymal stem 
cells (MSCs) have been used that, once differentiated into hepatocyte-like cells, offer a 
potentially unlimited source of cells for autologous transplant procedures (Ghaedi et al., 
2010). These human MSCs were transduced with a lentiviral AAT expression vector and 
were shown to express major hepatocyte marker genes and AAT. This technology has 
potential as an in vitro source of cells for transplantation therapy of liver diseases in AAT-
deficient patients.  Another angle on this approach is being developed by Li et al. (Li et al., 
2010). They assessed the feasibility of bone marrow (BM) cell-based liver gene delivery of 
human AAT. Their in vitro studies showed that both lentiviral and rAAV vectors expressing 
AAT can be transduced into these cells and transplanted into the liver where they 
differentiate into hepatocytes and express AAT, resulting in sustained levels of circulating 
AAT in the recipient mice. In another study they used adipose tissue as an abundant, 
accessible and replenishable source of adult stem cells (Li et al., 2011). Adipose tissue-
derived mesenchymal stem cells (AT-MSCs) resemble bone marrow-derived mesenchymal 
stem cells (BM-MSCs). Having investigated the feasibility of AT-MSC-based liver gene 
delivery for the treatment of AAT deficiency by transducing mouse AT-MSCs with an 
rAAV1 vector carrying the human AAT gene, it was shown that when the cells were then 
transplanted into the mouse liver that they expressed human AAT.  Importantly, no anti-
human AAT antibodies were detected. 
Human induced pluripotent stem cells (iPSC) also hold great promise for cell-based therapy 
and in cell studies of genetic diseases. A strategy using dermal fibroblasts from AAT-
deficient individuals has generated a library of patient-specific human iPSC cell lines 
(Rashid et al., 2010). Once differentiated into hepatocytes the resulting cells exhibit 
properties of mature hepatocytes and recapitulate key pathological features of AAT 
deficiency including accumulation of misfolded AAT in the endoplasmic reticulum. Using 
an approach such as this it may be possible to generate iPSC hepatocytes from an AAT-
deficient individual, repair the defect in vitro with for example SDFs, ribozymes or zinc 
finger nucleases and transplant these ‘corrected’ cells back into the original donor (Figure 2).  
The next step in advancing this technology will be to achieve this without the worry of 
endogenous effects mediated by reprogramming transgenes. A number of methods already 
exist for generating murine or neonatal iPSCs free of reprogramming transgenes however, 
until recently this was not the case for disease-specific iPSC from humans with inherited or 
degenerative diseases. Now a humanized version of a single lentiviral "stem cell cassette" 
vector to accomplish efficient reprogramming of normal or diseased skin fibroblasts 
obtained from humans has been developed (Somers et al., 2010). The human iPSCs 
generated using this vector contain a single viral integration that can excise to generate 
human iPSCs free of integrated transgenes. As a proof of principle, this strategy has been 
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used to generate lung disease-specific iPSC lines from individuals with AAT deficiency-
related emphysema. These cells have the ability to differentiate into developmental 
precursor tissue of lung epithelia and will prove invaluable for AAT-deficiency related 
investigations. However the most exciting aspect of this technology is its potential to 
generate safer autologous ‘corrected’ cell therapies similar to those described above.  
It is sometimes suggested that non-viral episomal plasmid DNA (pDNA) vectors may offer 
some advantages over viral vectors in that they can be produced cheaply and in large 
quantities. Argyros et al. developed such a vector using the human AAT promoter to drive 
expression of a luciferase gene and achieve long-term expression in murine liver (Argyros et 
al., 2008). Over the course of the study the vector was maintained as an episome and did not 
replicate.  Luciferase expression was detectable up to 6 months and this is believed to be by 
means of a unique scaffold/matrix attachment region (S/MAR) element that inhibits 
methylation of the AAT promoter. 
4. Conclusion  
Since the first human gene therapy trials using lymphocytes for the cellular delivery of the 
adenosine deaminase gene to patients with severe combined immune deficiency (SCID) and 
as tumour-infiltrating vehicles there has been a remarkable expansion in the development of 
gene therapy strategies (Culver et al., 1991a; 1991b; 1991c). The most promising data have 
come from therapies targeting monogenic disorders. With respect to ZAAT deficiency, 
rAAV2 vectors, and more recently rAAV1 due to its higher tropism for muscle cells, have 
shown great promise for delivery of the AAT gene. The advantages of AAV vectors include 
not only their lack of acute pathology but also their episomal nature. Occasional problems 
with adaptive immune responses to its capsid proteins have been encountered in some 
contexts (Manno et al., 2006), however newer generation vectors with greater safety and 
efficiency of gene transfer are constantly under development. Non-AAV gene therapy 
strategies for AAT-related lung disease, although less advanced, also show potential. 
Genetic therapies designed to down-regulate expression of ZAAT in hepatocytes to reverse 
the toxic gain of function in the liver are also less well developed, however the next decade 
is likely to see huge progress in this area. Finally the recent advent of various stem cell 
technologies can only enhance efforts in ZAAT deficiency and gene therapy research. 
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